No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Novo Nordisk A/S (NYSE:NVO) says that despite earlier warnings from the Danish Medicines Agency about potential shortages of Wegovy, it does not anticipate a shortage of its weight-loss drug in Denmark.
Novo Nordisk A/S(紐約證券交易所代碼:NVO)表示,儘管丹麥藥品管理局早些時候曾警告說Wegovy可能出現短缺,但預計其減肥藥物在丹麥不會短缺。
The agency had warned of limited supply for the 1 mg injection pen from late May to mid-June and the 0.5 mg injection pen from mid-June to mid-July due to increased demand.
該機構曾警告說,由於需求增加,從5月下旬到6月中旬,1毫克注射筆的供應有限,從6月中旬到7月中旬,0.5毫克注射筆的供應有限。
Also Read: What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk.
另請閱讀: 可能擴大醫療保險覆蓋範圍的Ozempic和Wegovy的定價策略是什麼?參議院委員會質疑諾和諾德。
In both cases, the expected shortage was due to rising demand, the medicines agency said.
該藥品機構表示,在這兩種情況下,預期的短缺都是由於需求增加造成的。
"Novo Nordisk is experiencing a high demand for Wegovy, which can result in periodic backorders of various doses of the product in Denmark," Novo Nordisk said in a statement to Reuters.
諾和諾德在給路透社的一份聲明中說:“諾和諾德對Wegovy的需求很高,這可能導致丹麥定期缺貨各種劑量的該產品。”
"In the case of Wegovy FlexTouch 1.0 mg and 0.5 mg, the announcements from the Danish Medicines Agency are no longer current," it said.
它說:“就Wegovy FlexTouch1.0毫克和0.5毫克而言,丹麥藥品管理局的公告已不再是最新的。”
Wegovy is given by weekly injection. It starts at 0.25 mg of the active ingredient semaglutide and gradually increases to a maintenance dose of 2.4 mg.
Wegovy 每週注射一次。它從活性成分索瑪魯肽的0.25 mg開始,然後逐漸增加到2.4 mg的維持劑量。
Novo, struggling with supply constraints due to run-away demand for the hugely popular drug, said all doses were available in Denmark.
由於對這種廣受歡迎的藥物的需求失控,Novo在供應限制中苦苦掙扎。Novo表示,所有劑量均可在丹麥上市。
Earlier this month, as per a media report, online pharmacies and slimming clinics in Britain are reducing prices for Novo Nordisk's Wegvoy and Eli Lilly And Co's (NYSE:LLY) Mounjaro as initial supply shortages ease, a move driven by growing competition among retailers.
據媒體報道,本月早些時候,隨着初始供應短缺的緩解,英國的在線藥房和減肥診所正在降低諾和諾德旗下的Wegvoy和Eli Lilly And Co(紐約證券交易所代碼:LLY)Mounjaro的價格,此舉是由零售商之間日益激烈的競爭所推動的。
In April, Novo Nordisk warned that starter kits for its widely used diabetes drug Ozempic (semaglutide) would not be available in Germany during the second quarter.
4月,諾和諾德警告說,其廣泛使用的糖尿病藥物Ozempic(索馬魯肽)的入門套件將在第二季度在德國上市。
Price Action: NVO shares are up 0.82% at $134.01 at last check Wednesday.
價格走勢:週三最後一次檢查時,NVO股價上漲0.82%,至134.01美元。
Image Via Shutterstock
圖片來自 Shutterstock